NetworkNewsBreaks Archive - Page 3 of 1951

FridayMay 16, 2025 11:24 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations…

FridayMay 16, 2025 10:00 am

NetworkNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Expands to Indonesia with AI Insurance Platform Through Mach Wireless Deal

FingerMotion (NASDAQ: FNGR), has entered the Indonesian market via its subsidiary, Finger Motion Financial Company Limited, by signing an agreement with PT Mach Wireless Teknologi to deploy its AI-driven insurance risk rating platform. Tailored for local underwriting in motor, health, and life insurance, the platform will integrate with Indonesia’s telco-insurance ecosystem. The company is in final talks with a major Indonesian telecom provider to support the rollout. This marks a key milestone in FingerMotion's Southeast Asia expansion strategy, blending AI, big data, and regional partnerships to transform digital insurance delivery. To view the full press release, visit https://nnw.fm/7VaEd About FingerMotion…

FridayMay 16, 2025 9:00 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the…

FridayMay 16, 2025 9:00 am

NetworkNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) CEO Highlights Vertical Integration and $184M Asset Base on GotStocks Podcast

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) President and CEO Dr. Richard Lu appeared on the GotStocks Podcast to discuss the company’s vertically integrated model and its $184 million portfolio of revenue-generating clean energy assets. Lu detailed how SolarBank develops, builds, owns, and operates distributed and community solar projects across Canada and the U.S., including partnerships with Honeywell and Qcells. He also highlighted a recent $100 million financing agreement with CIM Group to fund 97 MW of U.S. projects, positioning the company for continued long-term growth. To view the full press release, visit https://nnw.fm/V7HaW About SolarBank…

ThursdayMay 15, 2025 3:24 pm

NetworkNewsBreaks – Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based Care Engine and Patented Risk Engine, identify care gaps and high-risk patients, enabling earlier interventions that enhance both clinical and financial performance. By developing targeted solutions, with a focus on smaller and independent practices, Adageis…

ThursdayMay 15, 2025 2:36 pm

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl…

ThursdayMay 15, 2025 2:28 pm

NetworkNewsBreaks – Zacks Research Issues Business Update as Soligenix Inc. (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted this week in a Zacks Small-Cap Research report that presented a favorable analysis, noting that the company’s Phase 3 cutaneous T-cell lymphoma (“CTCL”) study is continuing and that the trial has a high probability of success. According to the report, Soligenix is conducting a Phase 3 FLASH2 trial of HyBryte(TM) in patients with CTCL. The Zacks report noted that the FLASH2 trial is similar in design to the recently completed successful Phase 3 FLASH trial. The one key difference between the trials is that in the FLASH trial…

ThursdayMay 15, 2025 12:37 pm

NetworkNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Surpasses 450 Accounts as Fingerprint Drug Testing Expands Globally

Intelligent Bio Solutions (NASDAQ: INBS) reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market. To view the full article, visit https://nnw.fm/tzRUc About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc.…

ThursdayMay 15, 2025 12:30 pm

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments such as ketamine and transcranial magnetic stimulation to treat severe depression and PTSD, with current contracts in place to serve veterans through the VA. Universal Capital expects to participate in future funding rounds as HOPE…

ThursdayMay 15, 2025 12:13 pm

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses

Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, as it advances systemic virotherapies targeting metastatic cancers. To view the full press release, visit: https://nnw.fm/2sdvH About Calidi Biotherapeutics Calidi Biotherapeutics…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks